Showing results (31-40 of 319) with videos related to
Sort By:
Pageof 32
The Oncologist|August 5, 2003
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failureAthanassios Argiris, Daniel J Haraf, Merrill S Kies, et al.Clinical Lung Cancer|May 16, 2009
PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histologyEverett E Vokes, Suresh Senan, Joseph A Treat, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
The cancer and leukemia group B respiratory committeeEverett E Vokes, Michael C Perry, Hedy L Kindler, et al.Journal of Oncology Practice|October 5, 2018
Management of Early Head and Neck Cancer in Elderly PatientsMichael J Jelinek, Adam S Howard, Daniel J Haraf, et al.American Journal of Clinical Oncology|August 3, 2005
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancerHedy Lee Kindler, Gregory Friberg, Linda Skoog, et al.Drugs of the Future|September 29, 2015
Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung CancerTobenna Nwizu, Rajani Kanteti, Ichiro Kawada, et al.Archives of Otolaryngology--Head & Neck Surgery|December 19, 2007
Aspiration in chemoradiated patients with head and neck cancerAlexander Langerman, Ellen Maccracken, Kristen Kasza, et al.Health Science Reports|October 12, 2020
Adjuvant treatment for high-risk salivary gland malignancies and prognostic stratification based on a 20-year single institution experienceBenjamin E Onderdonk, Everett E Vokes, Michael Gwede, et al.Sarcoma|June 4, 2008
Radiation-induced leiomyosarcoma: does antimetabolite chemotherapy contribute? A report of three casesBruce Brockstein, Arno Mundt, Daniel J Haraf, et al.Investigational New Drugs|May 4, 2004
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler, Anjali Avadhani, Kurombi Wade-Oliver, et al.Pageof 32